ASH 2022: Lymphomas and CLL

CME

Key Studies in Lymphomas and CLL: Independent Conference Coverage of ASH 2022

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 17, 2023

Expiration: April 16, 2024

John M. Burke
John M. Burke, MD
Peter Martin
Peter Martin, MD

Activity

Progress
1
Course Completed

Introduction

In this module, John M. Burke, MD, and Peter Martin, MD, discuss key findings in lymphoma and chronic lymphocytic leukemia (CLL) presented at the 2022 American Society of Hematology (ASH) Annual Meeting. 

Please note that the key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with lymphoma or CLL do you provide care for in a typical month?

When discussing treatment options with a 74-year-old patient with newly diagnosed mantle cell lymphoma (MCL), what would you tell them regarding failure-free survival (FFS) reported from the phase III TRIANGLE trial in previously untreated MCL, which compared the standard of care (SoC) of chemoimmunotherapy (CIT) followed by autologous stem cell transplant (ASCT) with either SoC plus ibrutinib or the ASCT-free option of CIT plus ibrutinib, each with ibrutinib maintenance therapy being given for 2 years?

Which of the following was reported at ASH 2022 for the phase Ib/II EPCORE NHL-2 trial evaluating the combination of epcoritamab and lenalidomide/rituximab (R2) in patients with treatment-naive or relapsed/refractory (R/R) follicular lymphoma (FL)?

The current SoC for advanced-stage classical Hodgkin lymphoma (cHL) is brentuximab vedotin in combination with doxorubicin/vinblastine/dacarbazine (AVD), with current research efforts in the frontline setting being focused on de-escalation strategies to ameliorate toxicity for these patients. In part B of the phase II SGN35-027 trial evaluating brentuximab vedotin/nivolumab in combination with doxorubicin/dacarbazine (AN + AD), where vinblastine was replaced by nivolumab, which of the following safety findings were reported in patients with newly diagnosed advanced-stage cHL?

Which of the following findings reported at ASH 2022 by Ryan and colleagues was observed in patients with newly diagnosed CLL/small lymphocytic lymphoma (SLL) and a TP53 mutation compared with the overall population in a single-arm phase II trial evaluating treatment with the acalabrutinib/venetoclax/obinutuzumab (AVO) triplet regimen?